Join us on the 23rd & 24th February in Manchester Central Convention Complex to celebrate the success of the 10th Annual Biomarkers Congress, the leading Biomarkers congress in Europe.

Expecting to bring together over 250 senior level delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions. The congress features 6 interactive streams:

• Biomarkers in Discovery and Development

• Biomarker Discovery, Verification & Validation

• Innovations In Biomarker Research

• Biomarkers in Clinical Development & Diagnostics

• Clinical Trials & Personalised Medicine

View the full agenda

In the lead up to the 10th Annual Biomarkers Congress Oxford Global catches up with David Henderson, Principal Scientist from Bayer HealthCare to discuss the importance of using biomarkers within personalised medicine.

There is much debate as to whether personalised medicine will transform the industry. How do you see personalised medicine being implementing in the long term? How could this effect the industry?

“Personalised medicine is already transforming the industry; the regulatory authorities are already very much behind the idea of personalised medicine, and they see this as a way of remarkably improving healthcare delivery. This means – and I am speaking once again for the area of oncology – that today if you reach out to the FDA or the EMA with a clinical trial protocol and you don’t have biomarkers included, there will be some very pointed questions asked and you will have to produce a very good argument as to why it is not necessary to evaluate biomarkers and stratify or pre-select the patients in your proposed trial.”

View the full interview

Oxford Global confirms the judges for the Poster Presentation Award

To celebrate the success of the Biomarkers Congress, Oxford Global will be hosting a champagne toast after the first day of presentations. During this drinks reception, Oxford Global will be awarding a poster presentation award of £3,000. The award will be decided by a panel of 4 judges made up from some of our esteemed congress speakers presenting at the congress. All poster presentations will be judged on style and content. The confirmed judges are:

• Elena S Izmailova, Sr. Director, Global Translational Medicine, Takeda Pharmaceuticals International, Inc.

• Dirk Cerneus, Director Science, Clinical Pharmacology, Astellas Pharma

• Jill Richardson, Director, Neuroinflamation DPU, GlaxoSmithKline

• Paul Germann, Head Preclinical Safety Germany, Abbvie

Poster presentations spaces are limited and available to all registered delegates paying for the two day congress. The cost of submitting your poster is £250 plus VAT. Contact us today to be in with a chance of winning £3,000!

Register Today!

Download the congress agenda to find out more

Registration will be closing soon. For further information on this or any of our upcoming congresses, please contact Danielle Dalby on +44 1865 248455 or by email on d.dalby@oxfordglobal.co.uk